Premium
Apolipoprotein AI and alcoholic liver disease
Author(s) -
Poynard Thierry,
Abella Annie,
Pig JeanPierre,
Naveau Sylvie,
Leluc Robert,
Chaput JeanClaude
Publication year - 1986
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840060628
Subject(s) - alcoholic liver disease , medicine , gastroenterology , cirrhosis
Abstract A prospective study of apolipoprotein AI has been undertaken in 581 alcoholic patients and in 100 controls in order to describe the changes of apolipoprotein AI according to the different stages of the alcoholic liver disease, to correlate the changes to serum liver tests and to estimate its diagnosis and prognostic value. Results showed that apolipoprotein AI concentration is highly related to the degree of liver injury, reaching a maximum in patients with steatosis (229 ± 90 mg per dl), beginning to decrease in patients with fibrosis (188 ± 88 mg per dl) and reaching a minimum in patients with severe cirrhosis (91 ± 46 mg per dl). Apolipoprotein AI had an independent and discriminative value for the diagnosis of fibrosis (p < 0.001) vs. steatosis and for the diagnosis of cirrhotic vs. noncirrhotic fibrosis (p < 0.001) or vs. acute alcoholic hepatitis without cirrhosis (p < 0.001). Cirrhotic patients with apolipoprotein AI less than 100 mg per dl had a lower survival rate at 1 year (62 ± 7%) than patients with greater value (80 ± 6%; p < 0.05), but this prognostic value disappeared in multivariate analysis when other known prognostic factors were taken into account.